MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Neutrophil Extracellular Traps Reveal Novel Inflammatory Signatures in Parkinson’s Disease and Multiple System Atrophy

    C. Ying, M. Zhang, ​H. Zhang, ​Y. Li, W. Mao, Y. Cai (Beijing, China)

    Objective: This cross-sectional study investigates neutrophil extracellular trap (NET) activation in Parkinson’s disease (PD) and multiple system atrophy (MSA) by quantifying plasma levels of NET-associated…
  • 2025 International Congress

    Phase 1 and 1b Pharmacodynamic Data Support Central Modulation of Lysosomal Pathways With BIIB122/DNL151, a LRRK2 Kinase Inhibitor: Insights for the LUMA Trial

    K. Fraser, A. Lang, L. Kalia, R. Hauser, J. Greenamyre, Y. Moroishi, J. Kluss, B. Hersh, K. Ferber, R. Maciuca, C. Paián-Ruiz, R. Llorens-Arenas, D. Jennings, S. Huntswork-Rodriguez, D. Graham (Tampa, USA)

    Objective: Evaluate the effects of BIIB122/DNL151 treatment on CSF levels of pRab10, a biomarker of CNS LRRK2 modulation, in a Phase 1 study in healthy…
  • 2025 International Congress

    Identification of Rigidity in Parkinson’s Disease Using Wearable Technology

    P. Sharma, C. Sotirakis, J. Huxley, J. Fitzgerald, C. Antoniades (Oxford, United Kingdom)

    Objective: To evaluate the capacity of upper limb kinematic measures, collected using wearable technology, in (a) capturing clinical rigidity in Parkinson’s disease (PD) and (b)…
  • 2025 International Congress

    Virtual Reality to Assess for Digital Biomarkers of Visual Hallucinations in Parkinson’s Disease

    K. Getchell, S. Hirczy, A. Lin (Seattle, USA)

    Objective: Use a novel virtual reality (VR) protocol to evaluate for potential digital biomarkers of visual hallucinations (VH) in Parkinson’s Disease (PD). Background: VH are common…
  • 2025 International Congress

    Characterization of neuronal exosomes purified from plasma of Parkinson’s Disease Chilean patients

    V. Urbina, C. Aguilera, E. Larraechea, D. Sepulveda, R. Vidal (Santiago, Chile)

    Objective: The diagnosis of PD is usually late and has only palliative treatments that seek to slow the progression of motor symptoms. These characteristics make…
  • 2025 International Congress

    Sex Differences for Autopsy-Confirmed Prodromal Lewy Body Dementia

    F. Dino, L. Gunn-Sandell, A. Tsai, D. Carter, Y. Wang, E. Bayram (Aurora, USA)

    Objective: To assess sex differences in prodromal Lewy body dementia (LBD) compared to Alzheimer’s disease (AD) Background: Identifying LBD at the prodromal stage can provide…
  • 2025 International Congress

    Cognitive Biases in Movement Disorders: Implications for Clinical Decision-Making and Patient Perception of Symptoms

    N. Choudhury, D. Buonadonna, B. Carr (Gainesvile, USA)

    Objective: To explore how cognitive biases affect decision-making in patients with movement disorders, including misjudgments in symptom perception, risk-taking in treatment decisions and adherence to…
  • 2025 International Congress

    Modeling Dementia in Patients with Parkinson’s Disease Years After DBS

    S. Gunawardena, E. Assaedi, T. George, C. Sonneborn, D. Floden (Cleveland, USA)

    Objective: The objective of this study is to identify pre-operative cognitive characteristics of patients who are candidates for deep brain stimulation surgery that may contribute…
  • 2025 International Congress

    Caution in the creation of Parkinson’s disease cognitive composites

    D. Gonzalez, A. Karstens, J. Fleisher, S. Patel, C. Goetz (Chicago, USA)

    Objective: To evaluate the structural validity of new cognitive composites in Parkinson’s disease (PCCs). Background: PCCs created from constituent tasks are promising in their single-index…
  • 2025 International Congress

    The PDCogniCare Toolkit: Developing a harmonised neuropsychological toolkit specific to Parkinson’s Disease

    E. Mccann, D. Pourzinal, D. Sriram, L. Mitchell, J. Liddle, A. Lehn, N. Dissanayaka (Herston, Australia)

    Objective: To critically evaluate neuropsychological measures predictive of cognitive decline in Parkinson’s disease (PD) with the aim of proposing a comprehensive, evidence-based neuropsychological toolkit specific…
  • « Previous Page
  • 1
  • …
  • 141
  • 142
  • 143
  • 144
  • 145
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Welcome to the MDS Abstracts Site
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley